The approval in the United States of an innovative treatment for breast cancer has caused great repercussions among oncologists and also among people diagnosed with breast cancer. Several media outlets have highlighted the new drug as a “hope for patients with breast cancer.” The drug in question is trastuzumabe-deruxtecan, also known as DS8201. The study's researchers Destiny1-breast01 announced in December 2019 at the world's largest event on breast cancer, the San Antonio Breast Cancer Symposium (SABCS 2019), in Texas, United States, the surprising results of the new drug. “We are truly faced with a revolutionary treatment. The results presented in the phase 2 study demonstrated tremendous benefits in patients with HER2-positive metastatic breast cancer, who had already undergone, on average, six types of treatments,” comments Dr. Lilian Arruda, clinical oncologist and medical coordinator of the IBCC Oncology Research Center.What is HER-2 positive breast cancerSome types of breast cancer have an increased number of HER-2 receptors on the cell surface (the doctor can check this profile using a battery of tests). This condition is known as HER-2 overexpression and contributes to uncontrolled cell growth, which is the main characteristic of cancer. That is why it is a more aggressive type of tumor.Who will have accessApproved in the USA on January 6, 2020, in Brazil, access to the drug is made available through research protocols. Several research centers in Brazil are recruiting patients for studies using the new drug. Dr. Lilian Arruda points out that one of the several advantages of participating in clinical research is the opportunity to take advantage of a medication or procedure that is not yet available by the Unified Health System (SUS) or that is not yet being marketed. The IBCC Oncology Clinical Research Center is one of the places that is recruiting patients for research with the new drug.Learn more: https://ibcc.org.br/pesquisa-clinica/Colaboração by Dr. Lilian Arruda - clinical oncologist and medical coordinator of the IBCC Oncology Research Center.
The Cura Project Institute will hold, on the 26th, in São Paulo, the “1 Patient Meeting — Understanding Cancer — Breast Edition”. The purpose of the event, whose Registration is free, is that breast cancer patients, friends, and family members learn about the main advances in the diagnosis and treatment of breast cancer through simple and didactic presentations.
The lectures, which will be given by renowned oncologists, will deal with various aspects of the neoplasm. Among the topics are the fertility and pregnancy of cancer patients, genetic mutations, immunotherapy and new therapies.
In addition, other issues highlighted at the conference will be the importance of clinical research in cancer, the role of institutions in informing about the disease, and the initiatives of entities to improve access to therapies in the country.
Check out the schedule:14:00 - Opening - Dr. GUSTAVO WERUTSKY 14:05 - Fertility and pregnancy of patients with breast cancer during and after treatment - Dr. RICARDO CAPONERO 14:30 - Genetic mutations for breast and ovarian cancer: diagnosis and impact on treatment 14:55 - The evolution of treatment and survival of metastatic breast cancer - Dr. DANIELA DORNELLES ROSA 15:45 - Immunotherapy for the treatment of breast cancer: what is it, and for which patients? - Dr. GUSTAVO WERUTSKY 16:10 - Interval 16:30 - The role of cancer research groups - Project AMAZONA - Dr. SERGIO DANIEL SIMON 16:50 - Society's engagement in the fight against cancer: Cura Project - FERNANDA SCHWYTER 17:10 - Access to new treatments: the role of civil associations in accessing new treatments - Dr. MAIRA CALEFFI 17:30 - Multiplying information - MARLENE OLIVEIRA 17:50 - Questions and Closing - Dr. DANIELA DORNELLES ROSA
The event takes place at the Intercontinental Hotel, Alameda Santos, No. 1123, Jardim Paulista, Capital, São Paulo, from 14:00 to 17:50 p.m. Spaces are limited.
How can clinical research in Brazil change this scenario?Nora Thormann, from Porto Alegre (RS), had lymphoma that developed around her breast implant. Cristina Santedicola, from Salvador (BA), faced non-Hodgkin lymphoma for four years. What brings these women closer together, in addition to the fight against cancer, is that both were only successful in their treatments because they participated in clinical research in the United States. While in that country there are more than 80 research centers for every 1 million inhabitants, in Brazil there are only two. The probability of dying after diagnosis is twice as high in Latin America as in the United States or Europe. The main barriers to the development of clinical research in Latin America, according to experts, include the lack of structure in national or regional organizations dedicated to cancer research, a limited number of qualified and specialized people (for example, statisticians, study monitors, and other operational members), lack of public recognition of the importance of clinical research, legal obstacles, and regulatory in some countries and, critically, the lack of funding to support research. The CURA Project Institute, a non-profit organization that was born from an initiative of the Latin American Cooperative Oncology Group - LACOG, has been acting on several fronts in order to promote and raise resources for carrying out clinical research. “We are a platform for interaction and engagement, which uses music, art, design, sports, fashion, and events to involve people and ambassadors in the fight against cancer. Through our initiatives, we can receive donations from individuals or legal entities, directly, with donations via the website or participation in charitable events, or indirectly”, explains psychologist Fernanda Schwyter, president of Cura.Faced with the tragic scenario in Brazil, private funding of clinical research is extremely important. According to oncologist Gilberto Amorim (D'OR Oncology), godfather of NeoSamba Search, funded by the CURA Project, “one of the benefits of carrying out more clinical research in Brazil is that there will be a greater opportunity for patients, especially those treated by the public network, to have more access to innovative drugs, to new treatments, and also to treatments that are already reference, reducing the difference between Brazil and large international centers. INCA data According to data released recently by the National Cancer Institute (INCA), for the triennial period 2020/2022, Brazil will have 625,000 new cases of the disease every year. Prostate and breast lead with more than 66,000 cases each year. “There was a 10% increase in breast cancer compared to 2018,” explains Amorim. The number of cervical cancers, mostly caused by HPV, will be 17,000 a year, but the oncologist warns that “it is a vaccine-preventable disease for girls and boys.” Obesity is a risk factor in 11 of 19 cancers. Sedentary lifestyle, smoking, excessive alcohol and poor diet -poor in vegetables, vegetables and fruits and rich in processed and industrialized products- increase the risk of 10 types of cancer, according to the Ministry of Health. For Fernanda, founder of Cura, it is essential that there be constant education and awareness among the population about the risk factors of neoplasms. In addition, the psychologist reinforces that research and the production of local knowledge are the main weapons to change the condition of our continent, in which most patients receives lower treatments than those received in other regions of the world. Only 1 to 3% of open studies in the world are open in Brazil, he says.www.projectocura.org
Green January, which was dedicated to the fight against cervical cancer, is closing with a major initiative, of which the Cura Project is proud to be a part. This is the campaign “Movement Brazil without cervical cancer”, launched through the union of medical societies and non-governmental organizations, led by the Brazilian Gynecological Tumors Group (EVA). The main objective of the action, developed on the participants' social networks, is to educate the population about the importance of the anti-HPV vaccine (Human Papillomavirus) so that girls who are currently at vaccination age (9 to 14 years) are the first generation without cervical cancer in Brazil, since the virus is responsible for 90% of cases of Disease. In addition, the campaign aims to make women aware of the importance of preventive gynecological exams such as Pap smears. Brazil has already incorporated the HPV vaccine into the national vaccination schedule. For girls in 2014 and for boys in 2017 (11 to 14 years old). However, the adherence rate is still insufficient. Data from the Ministry of Health indicate that more than half of the young population in Brazil is infected with HPV, which can cause various types of cancer: cervix, penis, anus and more recently it has been associated with throat cancer (tonsils and base of the tongue). According to the president of the Brazilian Gynecological Tumors Group (EVA), Angélica Nogueira Rodrigues, a study conducted in eight Brazilian capitals showed that only 8% of parents were aware of the HPV vaccine. However, according to the doctor, “when they were informed about vaccination, 90% of them said they would agree to vaccinate their children or be vaccinated.” Among the main proposals of the “Movement Brazil Without Cervical Cancer” campaign are vaccination within schools, following the successful model of vaccination coverage in other countries, and/or the approval of a law on the need to present a vaccine card upon enrollment in educational establishments. Cervical cancer affects more than 16,000 women in Brazil a year, leading to nearly 6 thousand patients died. It is the third most common cancer in the country and the fourth cause of cancer death in women. In the Northern region, it is the first, and the second in the Northeast and Midwest regions. However, it is a preventable and curable disease when diagnosed at an early stage. According to the president of the Cure Project, Fernanda Schwyter, “we all have responsibilities in our efforts to combat cancer, whether by taking adequate care of the patient or carrying out clinical research to discover better treatments, or adopting healthy lifestyle habits and, finally, avoiding the disease, when possible, with vaccination, as is the case of cervical cancer.” See the campaign folder:
A social media campaign, developed by the Cura Project, is bringing together oncologists, and other health professionals, in the search for resources to finance phase 3 of the Neosamba clinical research, which seeks study a way to prevent HER2-negative breast cancer from relapsing in the patient.The purpose of the action is for the participants - godparents and godmothers - to share a personalized link for online collection on their social networks and encourage their followers to donate to the research. Each of them sets a goal for its collection and a ranking shows the results of the donations. According to the president of Cura, Fernanda Schwyter, it is a healthy competition for a great cause. “It's a way we found to engage doctors in the search for private resources for clinical research against cancer, a chain of good,” she explains. For now, doctors Heloisa Resende (RJ), Susana Ramalho (RJ), Monique Binotto (RS), Alessandra Morelle (RS), and doctors José Bines (RJ), Tomas Reinert (RS), Gilberto Amorim (RJ), Gustavo Werutsky (RS), Dr. Eduardo Romero (SP) participate in the “gymkhana”, in addition by the psychologist and sexologist Flávia dos Santos (Bogotá- Colombia). The Cura website is also participating in the competition.
With the motto “The cure for cancer is in our hands”, the Cura Project has developed several activities aimed at the arts, music, fashion and entertainment, in order to develop a culture of philanthropy to finance clinical research in Brazil. Research Neosamba, coordinated and managed by LACOG - Latin American Cooperative Oncology Group, is 100% Brazilian and will be performed with SUS patients from 12 cancer centers, distributed in eight states. Learn more and participate: https://linktr.ee/projetocura
The important Christmas Show for the CURA Project Institute took place on December 13 in the city of Miami - FL. The event entitled Ready For Christmas took place as part of the Journey Through Brazilian Experience, a cultural activity held by the Consulate General of Brazil in Miami and included the presentation of the great Venezuelan interpreter and composer MARGER, accompanied by the Puerto Rican pianist and conductor JOSE NEGRONI and his jazz band, nominated 3 times for the Latin Grammy. The show was part of the box office dedicated to the Cura Project, as a way of integrating society Latin American in the fight against cancer.
The CURA Project Partner Clinic Seal was awarded to Clínica AMO, Salvador-BA. The seal was created to symbolize the recognition of the support of companies in maintaining the Cura Project. AMO is the first institution to receive the seal, as it has invested and financially supported the CURA Project since its founding in 2015.
Art Basel Miami, the largest art fair in the world, opened its doors to the public from December 5th to 8th, and curator Adriana Rede once again chose the Cura Project Institute as a social responsibility project, with the objective of publicizing our objectives and engaging the artistic community in the fight against cancer during the guided tour for Brazilians at the fair.
Miami Art Basel took place at the Miami Beach Convention Center, where 269 galleries (13 were Brazilian) were present, which exhibited works by more than 4 thousand artists from around the world, including paintings, sculptures, installations, photographs and videos.
Events and artistic encounters have the power to bring people together and transform feelings into actions. This has been the proposal of the Cura Project, which aims to raise funds for clinical cancer research. This year, the initiative will be present at Ready for Christmas, a cultural event held annually in Miami. Part of the box office will revert to Cura.
Fernanda Schwyter, founder of the association, explains that the initiative was born to be an avant-garde and transformative institution within society. For this reason, we chose art as the main tool for raising awareness. “We are a platform for interaction and engagement, which uses music, art, design, sports, fashion, and events to involve people and ambassadors in the fight against cancer. It is an honor to have the support of the Consulate General of Brazil in Miami, where we will be participating in Journey Through Brazilian Experiences, in partnership with the Brazil Foundation and Negroni's Trio”, to raise funds for the fight against cancer in Latin America, explains Fernanda Schwyter, founder of the Cura Project Institute.
Ready for Christmas will take place on December 13 at 8 pm at the Miami Dade Auditorium. This year, the event will feature a concert by interpreter and composer Marger, who will be accompanied by pianist and conductor Jose Negroni and his jazz band, nominated three times for the Latin Grammy.
Other information and tickets via the link https://brazilfoundation.org/event/ready-for-christmas/
The Cura Project Institute created an online vaccine with the goal of raising 25,000 reais for the initial expenses of phase III of the Neosamba research, which studies how to reduce the risk of a type of breast cancer returning to the patient. Access and contribute: http://vaka.me/743320 About the Research:Every year new cases of cancer are registered in Brazil. The latest survey by the National Cancer Institute (INCA) showed that, by December, 60,000 people will be diagnosed with the disease. How to reverse this picture? Experts in the field are betting on clinical research because of the possible expansion of access to new therapies, an improvement in quality of life and an increase in patient survival. With that in mind, doctors and civil society have come together to encourage the production of new studies in Brazil. One of the fruits of this union is the partnership between the Cura Project and 12 cancer centers, distributed in 8 Brazilian states. Everyone is looking for encouragement to start phase III of the Neosamba trial, which studies a way to prevent HER2-negative breast cancer from coming back. During the 2018 edition of ASCO, a conference of the American Society of Clinical Oncology, doctor José Bines was present to talk about the completion of phase II of Neosamba. Conducted by INCA, the trial investigated 118 patients with the purpose of evaluating whether the change in the order of drugs in the anthracycline and taxane class (some of the most common drugs used for chemotherapy) would make a difference in women's survival. It was suggested that treating them first with taxane and then with anthracyclines, and not the other way around, as was the previous standard, could bring more significant gains in progression-free survival and, especially, in overall survival. The study is moving towards phase III, when the number of people investigated is expanded for a longer period of time. However, resources are lacking to begin this process, which oncologist José Bines defines as a “confirmatory scientific study”. “The results of this analysis may redefine the best neoadjuvant chemotherapy treatment (performed before surgery) for women with locally advanced breast cancer. The conclusion could have an immediate global impact on the care of women with breast cancer. According to the INCA forecast, 60,000 new cases of the disease may occur by the end of 2019,” explains the expert. “This is a 100% Brazilian survey and 100% conducted with SUS patients. There is no relationship with the pharmaceutical industry. All stages of designing and conducting the study are carried out by the researchers themselves, and now with the Cura Project, which has helped us to raise funds for the completion of phase III”, concludes José Bines.Presentation of the clinical study
Centers involved in the research
About the Cura Project:The Cure Project was born to be a transformative piece within society. Its main objective is to raise funds for clinical research against cancer in Brazil. To this end, Cura seeks to combine science and creativity as its main tools for raising awareness of the importance of this cause. The initiative is linked to the Latin American Cooperative Oncology Group, LACOG, a non-profit organization that aims to develop, conduct and coordinate academic studies and clinical research in Latin America. Today, the Cura Project operates in Brazil and will soon arrive in Latin America and the Caribbean.
Dr. Thiago Bueno was announced the winner during the Best of ASCO® Annual Meeting, organized by LACOG on June 14-15, 2019 at the Hotel Transamérica in São Paulo/SP. Thiago Bueno de Oliveira has a PhD in Oncology from the Antônio Prudente Foundation; Senior Physician in the Department of Clinical Oncology; Leader of Clinical Oncology at the Head and Neck Reference Center of the AC Camargo Cancer Center; and Member of the Brazilian Head and Neck Cancer Group.
Check out Dr. Thiago's report about his research:My work, which has already been completed and was my doctoral thesis, involves the evaluation of circulating tumor cells (CTCs) analyzed in blood samples, before and after treatment in patients with locally advanced head and neck cancer. 83 patients with epidermoid carcinoma of the oral cavity, oropharynx, larynx and hypopharynx, with locally advanced disease and candidates for treatment with curative intent were included prospectively. CTCs were detected in 94 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of the patients, and the number of CTCs was significantly correlated with survival and response to treatment. For each increase of 1 CTC/ml before treatment, there was a significant increase of 18 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}, 16 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in the risk of disease recurrence or progression, and a reduction of 26 {46cf1cf1 a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in the chance of a complete response to treatment. In addition, the expression of biomarkers in CTCs, some of them with prognostic and predictive potential, was studied. Counting CTCs before treatment was also shown to be a potential predictor of benefit from the use of chemotherapy before (induction) radiation therapy. High CTC counts after treatment and unfavorable kinetics (significant increases in CTCs considering the values before and after treatment) were also correlated with worse survival. The relevance of the results lies in the possibility of identifying patients with a higher risk of death or disease recurrence for potential intensification of treatment to improve these outcomes. Thus, with the search for CTCs and biomarkers before and after treatment, it is possible to personalize the treatment employed to maximize the chances of cure and minimize the sequelae of the treatment, improving survival with quality of life. Below is a technical summary of the work and its results:Prognostic impact of circulating tumor cells and potential predictive role of treatment response in locally advanced epidermoid carcinoma of the head and neck. São Paulo; 2019. [Doctoral Thesis - Antônio Prudente Foundation].Introduction:The prognostic role of circulating tumor cells (CTCs) in locally advanced head and neck cancer (CCPLA) has not yet been determined, due to conflicting results in previous studies, most using cytokeratin-dependent techniques for the identification and counting of CTCs. The primary objective of this study is to determine the detection rate using the ISET method, the prognostic role and potential predictive role of CTCs in CCPLA.Methods:Prospectively, blood samples from patients with non-metastatic CCPLA, stages III/IV, were analyzed for CTCs before and after treatment, in two scenarios: initial curative surgery and adjuvant radiation therapy (RT) and candidates for non-surgical strategies (unresectable or organ preservation) with RT concomitant with chemotherapy (QT) or cetuximab, whether or not preceded by induction QT (QTI).Results:83 patients and the detection rate of CTCs were included. Baseline It was 94 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} (78/83). The CTC count was significantly correlated with survival, with a relative increase of 18 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} (HR=1.18; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.06-1.31; p<0.001), 16 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} at risk of progression (HR=1.16; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.04-1.28; p=0.004) and a reduction of 26 {46cf1a6c7461493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} na chance of a complete response to treatment (OR=0.74; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.58-0.95; p=0.022) for each increase in a CTC. Patients with CTCs < 6.5/mL had a two-year overall survival (OS) estimate of 85.6 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} x 22.9 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e12b94daa5b61391} for CTCs ≥ 6.5/mL (HR=0.18; 95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.06-0.49; P<0.0001) and patients with CTCs ≤ 3.8/mL an estimate of progression-free survival (PFS) at two years of 71.8 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} x 37 {46cf1a6c7461ff493d31bdca70d45967bd1 ce7048f85e123712b94daa5b61391} for CTCs > 3.8/mL (HR=0.32; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} :0.15-0.67; p=0.001). After treatment, high CTC counts (cutoff 6.6/mL) were significantly correlated with worse SG (HR=0.12; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.06-0.40; p<0.001) and SLP (HR=0.19; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f31bdca70967bd1ce7085f123712b94daa5b61391}: 0.06-0.59; p=0.001). In the non-surgical treatment subgroup (n=67), the presence of microemboli (ME) was significantly correlated with worse OS (HR=3.01; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.06-8.52; p=0.020) and SLP (HR=3.84; CI95 {46cf1a6c7461ffce493d31bdca70d9671bdca70d9671bdca70d9671bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d9671bdca707048f85e123712b94daa5b61391}: 1.62-9.11; p<0.001). In this subgroup, high CTCs (>3.8/mL) and ME were identified as potential predictors of the QTI benefit. MRP-7 expression in ME Baseline was related to the worst SG (HR=3.49; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.01-12.04; p=0.047) and SLP (HR=3.62; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.08-12.13; p=0.037) and expression of TFGβRI in CTCs after treatment for the worst OS (HR=3.60; 1.03-12.59; p=0.032). Expression of beta-tubulin III in CTCs was associated with worse OS in patients receiving QTI (p=0.012). Patients with favorable CTC kinetics had better OS (HR=0.22; IC95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.07-0.67; p=0.004) and SLP (HR=0.33; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.13-0.84; p=0.015).Conclusions:Count of CTCs Baseline were correlated with survival and response to treatment and, together with ME, are potential predictors of the benefit of QTI. High CTC counts after treatment and unfavorable kinetics were also prognostic. Biomarker expression in CTCs and ME plays a prognostic and predictive role in CCPLA.
The evening of Friday, June 14, 2019 was filled with good music and solidarity. Participants at the Best Of ASCO Congress and society in general participated in the show “Jazz for Oncological Research” with conductor Osmar Barutti and singer Alba Santos.
At the time there was also a presentation from the winner of the first Renata Thormann Procianoy scientific research prize to Dr. Thiago Bueno. Creating a culture of philanthropy, raising resources for scientific research, and encouraging young oncologists to develop research that helps in the search for a cure for cancer are among the Objectives of the award created by the Cura Project.The show took place at Blue Note in the city of São Paulo-SP and was supported by Armazem Entertainment.
Created by Cura, the Renata Thormann Procianoy award aims to create a culture of philanthropy, raise resources for scientific research, and encourage oncologists to develop research that helps in the search for a cure for cancer. The award was launched at the Best of ASCO conference, which took place from June 14-15, 2019. In its first edition, Brazilian papers submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO) were considered. A technical committee made up of research doctors associated with LACOG chose Dr. Thiago Bueno's work as the winner.
The award was inspired by the story Nora Thormann Porcianoy, who had the help of her daughter Renata Thormann Procianoy in the search for research that would help diagnose what was wrong with her breast implants. The daughter gave up everything to commit herself to this mission, which, after two years, resulted in the inclusion of Nora's case in a study coordinated by doctor Dr. Roberto Miranda at the MD Anderson Hospital, University of Texas — USA. Research identified and treated Nora. Some years later, with Nora having recovered from cancer, her daughter Renata died in a car accident in 2013. The family transformed pain into love with the decision to contribute to work involving research to cure cancer. Then, through the Cura Project, they made a donation to LACOG, an institution that develops and coordinates multicentric oncology research in Latin America, with headquarters in Brazil. Learn more about this story in the video below:
The prize trophy was created and donated by the artist Fernanda Frangetto
Fernanda Frangetto Maksoud, visual artist, works in different media: sculpture, installation, painting and drawing. He studied at the Centro Universitário de Belas Artes and specialized in sculpture at the Brazilian Museum of Sculpture, both in São Paulo. His works have been presented at art institutions in the USA and Brazil, such as the NARS Foundation (New York); DORCAM Doral Contemporary Art Museum, Marco Island Center for the Arts, Magnetic Pompano (Florida); Casa das Nações Unidas (Brasília); Marcos Amaro Foundation, Central Bank of Brazil and Brazilian Society of Japanese Culture (São Paulo). He created sculptures and trophies for the “São Paulo Association of Art Critics” (Prize APCA), or Fashion Brazil Miami. The City of Doral - Government Center, in Florida, invited her to create sculptures in honor of the national fight against cancer. These sculptures were donated to Doral City Hall,” Commissioners Office of Miami-Dade” and the “American Cancer Society”. At the special invitation of the “Cura Project Institute Association”, the “Renata Thormann Procianoy Award 2019” was designed. Fernanda Frangetto received the Grand Gold Award at the Bunkyo Hall and was one of the consecutive winners of the Focus Brazil Visual Arts Award. Fernanda Frangetto has lectured at numerous art events and her works are included in collections such as the Consulate General of Brazil in Miami, the Marcos Amaro Foundation and the Brazilian Society for Japanese Culture. Fernanda Frangetto is represented by the Duo Art Gallery in Miami.
Make a donation to the Cura Project and guarantee your ticket to the concert of the Spanish singer Alba and conductor Osmar Barutti.
On 14/06, at Blue Note São Paulo, the Spanish singer Alba and the conductor Osmar Barutti, known for being the arranger of the show Jô Soares, come together for a very special evening where they present reinterpretations of the great jazz standards by composers such as Duke Ellington, Ira & George Gershwin, etc...
During the Show, the 1st Renata Thormann Procianoy Prize will be awarded as an incentive and recognition to the young researcher doctor and to encourage philanthropy.
SEP 2. — BENEFIT SHOW
LOCAL — BLUE NOTE São Paulo - Av. Paulista, 2073 - National Complex - Consolação, São Paulo - SP
DATE — 14/06
SCHEDULE — The Blue Note balcony with a view of Av. Paulista will be available to event guests starting at 8 p.m. Expected start of the show at 22:30.
MINIMUM AMOUNT FOR DONATION — R$ 200.00 (each R$ 200.00 in donation will entitle you to a ticket)
BOX OFFICE CONTACT — (11) 94545-1511 (WhatsApp)
Donations can be made safely through the platforms PayPal (for a minimum donation or a larger amount) or PagSeguro (for minimum donation)
If you prefer, it is still possible to make your donation by bank transfer to the account below. After the deposit, please send the receipt, your name and CPF/CNPJ number to contato@cura.supersoma.me.
Cura Project Institute Association
CNPJ: 033,188,607/0001-04
Banco Santander (Bank Code: 033)
Agency: 0995
Current Account: 13,001,079-8
Upon confirmation of payment, our team will contact you to indicate the procedure for collecting the tickets.
On June 14, in São Paulo-SP, the Spanish singer Alba and the conductor Osmar Barutti, known for being the arranger of the show Jô Soares, come together for a very special evening where they present reinterpretations of the great jazz standards by composers such as Duke Ellington, Ira & George Gershwin, etc... The show aims to raise funds for cancer research.
SEP 2. - LOCAL BENEFIT SHOW - BLUE NOTE São Paulo - Av. Paulista, 2073 - Consolação, São Paulo - SPDATE - 14/06SCHEDULE — 22:30 - The Blue Note balcony overlooking Av. Paulista will be open starting at 8 p.m.DONATION AMOUNT - $200.00 (Donors will win 1 ticket for the SET 2 show.) Soon we will announce how you can purchase your vacancy. This initiative is supported by:
Check out the interview with Dr. Otto Mezinger, an oncologist at the Dana Faber Cancer Institute and the Havard Medicine School.
Art Basel Miami, one of the leading global art fairs, had the Cura Project Institute as a social responsibility entity supported by Brazilian curator Adriana Rede's 2018 program.
The theme of the fair this year was Modern and Contemporary art. Among the participants in the fair was visual artist and photographer Vik Muniz, one of the most important Brazilian artists on the world stage. He is currently known for using unusual materials in his works, such as garbage, sugar and chocolate.
The president of Cura, Fernanda Schwyter, participated in the course “The Artistic Vanguards”, the lecture “Women in Art”, as part of the Miami Art Week activities, and also of the visit monitored by the curator, at the Miami Art Basel Fair. We did a short interview with Curator Adriana Rede:1- What is the importance of Art Basel Miami?Miami Art Basel, the largest art fair in the United States, brings together 268 galleries from 34 countries. It is considered the most important fair in the world for the Latin American art market. In 2018, 14 Brazilian galleries participated, with renowned national and international artists. Its importance in the art system is due to the dissemination of thought and educational process through issues addressed in art, both in the past and in our time.2- Why did you support CURA? Or what is the importance of this partnership?Today, political/social issues are part of the contemporary art repertoire and many artists and museum institutions have been involved with specific projects. For me, supporting CURA and its dissemination are a form of engagement, being at the forefront of future trends with the tools I have as a curator.
Fernanda Schwyter, president of the Cura Project Institute, and the curator Adriana Rede. Adriana Rede, has a degree in Social Communication, Curatorship, Expography and Art Criticism. She co-curated at MAM SP and curated exhibitions at museums such as MAJ Joinville, SESC Curitiba, Caixa Cultural SP and MAC USP. For 12 years, she has been curator of the charity exhibition Chapel Art Show, which has existed for 50 years and with more than 100 participating artists. Curator responsible for the Chapel Art Collection collection and editorial coordination of the publications in the collection. She curated individual shows by several artists: Florian Raiss (2009), Baravelli (2010), Antonio Henrique Amaral (2011), Claudio Tozzi (2012), Judith Lauand (2014), Nelson Leirner (2015), Katia Canton (2015), Hugo França (2017), German Lorca (2017), Ricardo de Vicq (2018/Germany) Curator of the official exhibition of the Curitiba Biennial circuit - 25 years. Member of the APCA-São Paulo Art Critics Association. Speaker in Brazil and abroad.
Cura, in partnership with Grupo Barbosa Lima, is promoting the holding of 12 musical performances, with artists from different genres of Brazilian music, such as: samba, rock, instrumental, MPB, among others. The income from the Shows will be used to finance research in the area of oncology. The project is collected through the Tax Incentive Law, such as ICMS, ISS and IPTU, both from legal entities and individuals.Against games:
The Cura Project was selected to be one of the programs supported by the Brazil Foundation. The campaign began on September 27 and will end on November 27. Help transform science into treatment. Research Saves Lives! Embrace CURA yourself too! Make your donation at the link: https://abraceobrasil.org/pt-br/projetos/projetocura/
Dr. Gustavo Werutsky, comments directly from Munich, Germany during the European Oncology Congress - ESMO, some examples of clinical research promoted by LACOG.
Dr. Marcio Debiasi, comments directly from Munich, Germany during the European Oncology Congress - ESMO, on the importance of the CURA project for the development of clinical research in Brazil.
Dr. Carlos Barrios, comments directly from Munich, Germany during the European Oncology Congress - ESMO, on the importance of clinical research in the evolution of cancer treatments.
Today I would like to share with you another practical example showing the importance of carrying out researches, here in Brazil (and in South America?) , at all levels and areas, since the main benefitted is the civil society itself, in other words, each one of us.Dr. Luciano Lauria Dib, a bucomaxillofacial surgeon, faculty member and researcher associated with international universities, in collaboration with Dr. Rodrigo Salazar, a Peruvian researcher, and the University of Illinois, USA, and additional physicians, invented an innovative and much cheaper method to manufacture facial prostheses. This new technique allows them to produce facial prostheses using a regular smartphone, free applications and a common 3-D printer.In addition to saving time and money, such technique enables the restoration of faces and also of the self-esteem among patients who suffered injuries associated with cancer of the mouth, nose, jaw or another area of head or neck.As one can see in previous posts published here on the CURE website, the incidence of cancer of head and neck (many of them associated with the HPV virus) has been increasing in a significant manner. According to statistics published by the Brazilian Ministry of Health, this type of cancer may reach up to 30,000 cases per year (in a near future?) ; as a consequence of such disease, surgical removal of portions of face is required, followed by some type of facial reconstruction. However, many of such patients cannot afford those restorative surgeries.Concerned with such scenario Dr. Dib, in conjunction with a multidisciplinary team — all volunteers, created the Instituto Mais Identidade, a non-for-profit organization, to restore the self-esteem of those patients who had their facial appearance modified. This Institute sponsors the installation of such innovative prostheses in such patients and plans to train additional physicians to use that technique.However, like the CURE Project, the Instituto Mais Identidade still suffers with the lack of resources to disseminate such benefits to thousands of patients.
We need a society more aware of the importance of supporting social responsibility projects and creating a culture of donation, both physical and legal, in order to allow these projects to advance, ranging from the scientific researches to the end product, be it a new medicine, a new treatment or a new technique.By Fernanda Schwyter Coordinator, CURE Project
Faça como a boutique da designer de moda Adriana Degreas e a clínica do Dr. Jose Couto: mostre para todos seu apoio ao Projeto Cura! Adquira os adesivos do Cura e apoie a luta contra o câncer. Escreva para fernanda.schwyter@lacog.org.br
The ceremony for awarding the certificates of the new CURA Ambassadors took place during the Best Of Asco Congress, on June 15 and 16 in the city of São Paulo. From left to right, Dr. Gustavo Werustky - Director of LACOG; Ambassador Dr. Luis Fernando Correia - doctor and journalist for CBN and Globo News; Ambassador Dr. Jorge Landemann - businessman; Dr. MaX Mano - LACOG Oncologist, Fernanda Schwyter - Director of the CURA Project; Dr. Carlos Barrios - President of LACOG.
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
